Want to see SLGL full AI Analyst Report?
SLGL Stock Chart & Stats
$81.72
-$2.13(-2.60%)
At close: 4:00 PM EDT
$81.72
-$2.13(-2.60%)
Day’s Range― - ―
52-Week Range$28.81 - $97.97
Previous Close$79.83
Volume47.21K
Average Volume (3M)54.21K
Market Cap
$234.97M
Enterprise Value$195.32M
Total Cash (Recent Filing)$30.47M
Total Debt (Recent Filing)$1.39M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Nov 05, 2026EPS Estimate
-2.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.97
Shares Outstanding3,273,999
10 Day Avg. Volume37,654
30 Day Avg. Volume54,213
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)5.15
Price to Sales (P/S)6.06
P/FCF Ratio426.90
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue29.78
Enterprise Value/Gross Profit81.79
Enterprise Value/Ebitda-59.32
Forecast
1Y Price Target
$152.50Price Target Upside86.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-8.88
Revenue Forecast (FY)$708.00K
Bulls Say, Bears Say
Bulls Say
Commercial Dermatology PlatformAn established dermatology platform with marketed prescription products provides an existing commercial foundation while supporting future topical therapies. The combination of product sales and specialized formulation capabilities can improve customer familiarity, leverage development know-how, and create a durable base for pipeline expansion.
Phase 3 Pipeline AdvancementCompletion of patient visits moves SGT-610 from active trial execution toward a definitive data readout, reducing a major development milestone risk. If results support approval, the candidate could add a differentiated topical treatment for a rare disease with limited options and expand Sol-Gel’s commercial platform.
Cash Runway And Conservative LeverageThe reported cash position and low debt provide meaningful operating flexibility for clinical development and preparation of a focused launch. Funding visibility into early 2028 may reduce near-term financing pressure, while conservative leverage limits interest and refinancing burdens as the pipeline advances.
Bears Say
Sharp Revenue Volatility And Ongoing LossesThe steep quarterly revenue decline and return to a net loss show that reported earnings remain highly volatile and are not yet supported by a consistently profitable commercial base. Continued dependence on uneven revenue sources could constrain reinvestment and make durable cash generation difficult to establish.
Cumulative Losses Eroding EquityAlthough leverage is low, the shrinking equity base indicates that cumulative losses have reduced financial capacity over time. Persistent capital erosion can narrow strategic flexibility, increase reliance on future financing or commercialization success, and leave less balance-sheet support if operating improvements do not persist.
Clinical And Regulatory Outcome DependencyA significant part of the future opportunity depends on successful clinical results and regulatory approval for SGT-610, which remain unresolved after trial completion. An unfavorable readout or regulatory outcome would delay commercialization and weaken the expected expansion of Sol-Gel’s rare-dermatology franchise.
Sol-Gel Technologies News
SLGL FAQ
What was Sol-Gel Technologies’s price range in the past 12 months?
Sol-Gel Technologies lowest stock price was $28.81 and its highest was $97.97 in the past 12 months.
What is Sol-Gel Technologies’s market cap?
Sol-Gel Technologies’s market cap is $234.97M.
When is Sol-Gel Technologies’s upcoming earnings report date?
Sol-Gel Technologies’s upcoming earnings report date is Nov 05, 2026 which is in 25 days.
How were Sol-Gel Technologies’s earnings last quarter?
Sol-Gel Technologies released its earnings results on Aug 20, 2026. The company reported -$1.13 earnings per share for the quarter, beating the consensus estimate of -$2.36 by $1.23.
Is Sol-Gel Technologies overvalued?
According to Wall Street analysts Sol-Gel Technologies’s price is currently Undervalued.
Does Sol-Gel Technologies pay dividends?
Sol-Gel Technologies does not currently pay dividends.
What is Sol-Gel Technologies’s EPS estimate?
Sol-Gel Technologies’s EPS estimate is -2.28.
How many shares outstanding does Sol-Gel Technologies have?
Sol-Gel Technologies has 3,273,999 shares outstanding.
What happened to Sol-Gel Technologies’s price movement after its last earnings report?
Sol-Gel Technologies reported an EPS of -$1.13 in its last earnings report, beating expectations of -$2.36. Following the earnings report the stock price went down -0.121%.
Which hedge fund is a major shareholder of Sol-Gel Technologies?
Currently, no hedge funds are holding shares in SLGL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sol-Gel Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$152.50 (86.61% Upside)
$152.50 (86.61% Upside)
Blogger Sentiment
Neutral
SLGL Sentiment 50%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth $3.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.2%
Last 30 Days ▼ 13.5%
Last 30 Days ▼ 13.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
81.00%
12-Months-Change
Fundamentals
Return on Equity
-44.05%
Trailing 12-Months
Asset Growth
36.76%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Sol-Gel Technologies
Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities centered in Israel. Sol-Gel's pipeline features several key candidates. Twyneo, an innovative, non-antibiotic topical cream designed for once-daily application, has successfully concluded Phase III trials for treating acne vulgaris. Similarly, Epsolay, another topical cream administered once a day, has also completed its Phase III studies, targeting papulopustular rosacea. Advancing through Phase I clinical trials is SGT-210, intended for palmoplantar keratoderma. Furthermore, the company is investigating Erlotinib, Tapinarof, and Roflumilast as potential treatments for psoriasis and various other medical conditions. Beyond its proprietary offerings, the company also engages in creating generic versions of topical dermatological medications. Sol-Gel Technologies maintains a strategic partnership with Perrigo. Established in 1997, the company maintains its headquarters in Ness Ziona, Israel.
SLGL Stock 12 Month Forecast
Average Price Target
$152.50
▲(86.61% Upside)
Technical Analysis
Insight Molecular Diagnostics
―
Ovid Therapeutics
―
Shattuck Labs
―
Surrozen
―
Metagenomi, Inc.
―
Ownership Overview
16.95% Insiders
0.04% Mutual Funds
38.18% Other Institutional Investors
43.92% Public Companies and
Individual Investors